AUTHOR=Xu Yifan , Jiang Jin , Wang Yutong , Wang Wei , Li Haokun , Lai Wenyu , Zhou Zhipeng , Zhu Wei , Xiang Zheng , Wang Zhiming , Zhu Zhe , Yu Lingfeng , Huang Xiaolan , Zheng Hua , Wu Sha 

TITLE=Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

JOURNAL=Frontiers in Immunology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.725330

DOI=10.3389/fimmu.2021.725330

ISSN=1664-3224

ABSTRACT=<p>Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.</p>